Trial Profile
A Phase II, Open-Label, Multi-Center Study of PDS0101 and Pembrolizumab (KEYTRUDA) Combination Immunotherapy in Subjects With Recurrent and/or Metastatic HNSCC and High-Risk HPV16 Infection
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs PDS 0101 (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms VERSATILE-002
- Sponsors PDS Biotechnology Corporation
- 24 Oct 2023 Results (n=18) of an analysis assessing cytokines and chemokines associated with a predominant effector, stimulatory functional profile presented at the 48th European Society for Medical Oncology Congress
- 23 Oct 2023 According to a PDS Biotechnology Corporation media release, announced immune response data from a preliminary analysis of a subset of patients in VERSATILE-002, the Phase 2 clinical trial evaluating the safety and efficacy of PDS0101 in combination with Merck & Co.s anti-PD-1 therapy (pembrolizumab) in patients with human papillomavirus (HPV)16-positive recurrent or metastatic head and neck squamous cell carcinoma. The data presented during the European Society for Medical Oncology Co
- 23 Oct 2023 Results presented in PDS Biotechnology Corporation media release.